Prostate-specific antigen (PSA) screening is associated with decreased risk of prostate cancer-specific mortality (PCSM) among both Black and White men, according to a study published online Aug. 4 in JAMA Oncology.
Michael V. Sherer, M.D., from the University of California in San Diego, and colleagues compared outcomes after PSA screening among non-Hispanic Black and non-Hispanic White men. Analysis included 45,834 U.S. veterans (aged 55 to 69 years) who were diagnosed with intermediate-, high-, or very high-risk prostate cancer between 2004 and 2017.
The researchers found that the PSA screening rate was associated with a lower risk of PCSM among Black men (subdistribution hazard ratio [sHR], 0.56; 95 percent confidence interval [CI], how long does ecstasy stay detectable in urine 0.41 to 0.76; P = 0.001) and White men (sHR, 0.58; 95 percent CI, 0.46 to 0.75; P = 0.001). Annual screening versus some screening was associated with a significant reduction in risk of PCSM among Black men (sHR, 0.65; 95 percent CI, 0.46 to 0.92; P = 0.02) but not among White men (sHR, 0.91; 95 percent CI, 0.74 to 1.11; P = 0.35).
Source: Read Full Article